

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

117-231

APPLICANT

MACLEAN et al

FILING DATE

28 January 1997

(To Be Assigned)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
See	WO 92/13943	08/20/92	EPO				
	WO 92/04050	03/19/92	USA				
	WO 93/19591	10/14/93	USA				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)

See	NEUROSURGERY, Vol. 32, NO. 4, April 1993; pp 597-603, MARKERT et al; 'Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain et al'
1	SCIENCE, Vol. 250, 1990; pp 1262-1266; CHOU et al; 'Mapping of Herpes Simplex Virus-1 Neurovirulence to γ_1 34.5, a Gene Nonessential for Growth in Culture'
	VIROL 70, (1989), pp 705-716; TAHA et al; 'A Variant of Herpes Simplex Virus Type 2 Strain HG52 with a 1.5 kb Deletion in R, between 0 to 0.02 and 0.81 to 0.83 Map Units Is Non-neurovirulent for Mice'
	GENE THERAPY 1, 1994, PP 323-331; BOVIATIS et al; 'Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or et al'
	VIROL. 69, 1988, PP 1531-1574; McGEACH et al; 'The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1'
	NAT. ACAD. SCI. USA; Vol 86, pp 4736-4740; COEN et al; 'Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate'
	SCIENCE 252; 1991, PP 854-856; MARTUZA et al; 'Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant'

*Examiner

Date Considered

3/8/98

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

Form PTO-FB-A820 (Also PTO-1449)